The most frequent adverse events (AEs) were nasopharyngitis and upper respiratory tract infections in all treatment groups.<h4>Conclusion</h4>There is increasing evidence on the use of drugs targeting the JAK/STAT pathway as a treatment for psoriasis, although they are in the early phases of development. This evidence concerns the gene SOAT1 and psoriasis.